Erasca dips on patient death
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
